Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Brad Kahl MD

Brad Kahl MD

Professor of Medicine, Washington University School of Medicine; Director, Lymphoma Program, Washington University, St. Louis, MO

Brad Kahl, MD, is a professor of medicine and director of the lymphoma program at Washington University School of Medicine, St. Louis. He earned his medical degree from Tufts University School of Medicine, Boston. He then completed a residency in internal medicine, a year as chief resident, and a fellowship in hematology at the University of Wisconsin.

Dr. Kahl’s research focuses on improving outcomes for patients with lymphoma through testing novel agents and regimens in well-designed clinical trials. He is Chair of the ECOG-ACRIN lymphoma committee since 2009 where he has facilitated the development of multiple large clinical trials. Dr. Kahl is a member of several professional societies, including the American Society of Hematology, American Society of Clinical Oncology, ECOG-ACRIN, and the National Cancer Institute Lymphoma Steering Committee and the Lymphoma Research Foundation Scientific Advisory Board.


Dr. Kahl reports the following disclosures:

Commercial Interests - Consultant

Astrazeneca, ADCT Therapeutics, Roche, Genetech, Abbvie, MEI, AcertaPharma, Pharmacyclics, Celgene, Beigene, Kite, Morphosys, Karopharm, Janssen, TG Therapeutics


Genetech - Various Agents, Abbvie - Venetoclax, Celgene/BMS - Liso-Cel, BeiGene-Zanubrutinib, Genmab-Epcoritamab, MEI - Zandelisib, TG Therapeutics - Umbralisib